SCHEMBL16740802

SCHEMBL16740802

CCc1nc2c(F)cc(F)cc2n1-c1nc(N)nc(Nc2ccc(OC(F)F)c(F)c2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMI1 P35226 5/20 0.40
CYBB P04839 1/20 0.33
NOX5 Q96PH1 1/20 0.33
NOX3 Q9HBY0 1/20 0.33
NOX4 Q9NPH5 1/20 0.33
NOX1 Q9Y5S8 1/20 0.33
P2RX3 P56373 4/20 0.33
TERT O14746 1/20 0.32
HTR1A P08908 1/20 0.32
DRD2 P14416 1/20 0.32
HTR2A P28223 1/20 0.32
HTR7 P34969 1/20 0.32
HTR6 P50406 1/20 0.32
AGPAT2 O15120 1/20 0.32
ROCK2 O75116 1/20 0.31
P2RX7 Q99572 1/20 0.31
GALR2 O43603 1/20 0.31
HTT P42858 1/20 0.31
SCN9A Q15858 1/20 0.31
EHMT2 Q96KQ7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16748420 0.90 BMI1 (0.39) BMI1CYBBNOX5NOX3NOX4
SCHEMBL16740781 0.90 BMI1 (0.38) BMI1CYBBNOX5NOX3NOX4
SCHEMBL16740783 0.90 BMI1 (0.50) BMI1GALR2HTT
SCHEMBL16740854 0.88 BMI1 (0.53) BMI1CYBBNOX5NOX3NOX4
SCHEMBL15747480 0.87 BMI1 (0.37) BMI1P2RX3P2RX7
SCHEMBL16740795 0.86 BMI1 (0.45) BMI1CYBBNOX5NOX3NOX4
SCHEMBL16740761 0.85 BMI1 (0.49) BMI1
SCHEMBL16748425 0.85 MAPK1 (0.36) BMI1CYBBNOX5NOX3NOX4
SCHEMBL16748593 0.84 CYBB (0.42) BMI1CYBBNOX5NOX3NOX4
SCHEMBL16748506 0.84 BMI1 (0.35) BMI1CYBBNOX5NOX3NOX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B BMI1 1/4885CYBB 4251/4885NOX5 3227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.